中国合理用药探索2025，Vol.22Issue(4)：12-22,11.DOI:10.3969/j.issn.2096-3327.2025.04.002
非紫杉烷类微管蛋白抑制剂的药品遴选量化评估
Quantitative Evaluation for Drug Selection of Non-Taxane Tubulin Inhibitors
摘要
Abstract
Objective:To conduct a quantitative evaluation for the selection of non-taxane tubulin inhibitors,such as utidelone,eribulin,and vinorelbine,providing in hospitals with experience and evidence-based guidance for the selection and rational use of these drugs.Methods:With reference to the A Quick Guideline to Drug Evaluation and Selection in Chinese Medical Institutions,the quantitative scoring of utidelone,eribulin and vinorelbine using a scoring system out of 100 points was conducted based on five key dimensions of pharmaceutical properties,efficacy,safety,economy and others such as national medical insurance through collecting general data on the pharmacodynamics and pharmacokinetics of these drugs as well as evidence-based medical evidence regarding their efficacy and safety.The scoring results were used to assign recommendation levels for each drug.Results:Eribulin scored 75.47 points,with its advantages primarily reflected in pharmaceutical properties,safety and economy.Vinorelbine scored 69.60 points,with its advantages primarily reflected in efficacy and economy.Utidelone scored 63.17 points,lacking advantages in safety due to insufficient research on special populations and also showing no advantage in economy.The three drugs scored consistently in terms of efficacy.Conclusion:Eribulin is strongly recommended,while vinorelbine and utidelone are weakly recommended.The recommendation ranking is as follows:eribulin>vinorelbine>utidelone.关键词
晚期乳腺癌/紫杉烷类/蒽环类/优替德隆/艾立布林/长春瑞滨/药品评价Key words
advanced breast cancer/taxanes tubulin/anthraycline/utidelone/eribulin/vinorelbine/drug evaluation分类
药学引用本文复制引用
冯彩萍,庄捷,孙红,蔡加琴,李萍,魏晓霞..非紫杉烷类微管蛋白抑制剂的药品遴选量化评估[J].中国合理用药探索,2025,22(4):12-22,11.基金项目
福建省自然科学基金(2021J01397) （2021J01397）
福建省科技创新联合资金项目(2023Y9347) （2023Y9347）
福建省卫生健康科技计划(2022GGA010) （2022GGA010）
